Market Segmentation:
- By Product Type
- Olaparib
- Rucaparib
- Niraparib
- Talazoparib
- Others (Veliparib, Pamiparib, etc.)
- By Cancer Type
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Pancreatic Cancer
- Others (Colorectal, Gastric, etc.)
- By Biomarker Type
- BRCA Mutations
- HRR Gene Mutations
- PARP Expression
- Others (SLFN11, ETS, etc.)
- By Therapy
- Monotherapy
- Combination Therapy
- By End User
- Hospitals
- Specialty Clinics
- Cancer Research Centers
- Others (Diagnostic Laboratories, etc.)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Drug Stores, etc.)
- By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the PARP Inhibitor Biomarkers industry is USD 2.8 billion in 2023.
Increasing cancer prevalence globally, rising adoption of biomarker testing, favorable reimbursement policies for treatment, and growing pipeline of PARP inhibitors.
High treatment costs of therapy, lack of awareness in underdeveloped regions, patent expiries of leading drugs, and drug resistance and side effects.
The leading component segment in the PARP Inhibitor Biomarkers Market is the olaparib segment, used for treating various cancers like ovarian, breast, and prostate.
AstraZeneca, GlaxoSmithKline, Clovis Oncology, Pfizer, Merck & Co., Abbvie, Eisai Co., Repare Therapeutics, Artios Pharma, and Oncologie.
The North America region is expected to lead the PARP Inhibitor Biomarkers Market, with a projected market size of USD 10.0 billion by 2031 and a CAGR of 17.2% during 2024-2031.
Increasing cancer prevalence, rising adoption of biomarker testing, favorable reimbursement policies, growing pipeline of PARP inhibitors, advancements in diagnostics, and emergence of novel drug delivery systems.